scholarly journals An Updated Review of Randomized Clinical Trials Testing the Improvement of Cognitive Function of Ginkgo biloba Extract in Healthy People and Alzheimer’s Patients

2020 ◽  
Vol 10 ◽  
Author(s):  
Haolong Liu ◽  
Min Ye ◽  
Hongzhu Guo
2019 ◽  
Vol 16 (10) ◽  
pp. 919-933 ◽  
Author(s):  
Alicia Ruiz-Muelle ◽  
María Mar López-Rodríguez

Background: In recent years, several reviews have addressed the effectiveness of dance therapy in dementia, healthy older adults, or the elderly in general. However, reviews regarding the effect of this therapy exclusively on patients diagnosed with Alzheimer’s disease have not been found. Objective: The purpose of this study is to review the available literature describing clinical trials which explore the effects of dancing on psychological and physical outcomes, functionality, cognitive function, and quality of life in patients diagnosed with Alzheimer’s disease. In addition, this review aims to assess the quality of studies that perform dance therapy interventions in these patients. Methods: This study is a systematic review of randomized and non-randomized clinical trials regarding the effect of intervention including a dancing activity in people diagnosed with Alzheimer's disease. Results: In total, the evidence for this review rests on 12 studies with a total of 349 participants. The findings of this mini-review confirm the positive effect of dance therapy on physical and cognitive function, functionality, psychological outcomes, and quality of life in people with Alzheimer's disease. Conclusion: Most of the studies implementing dance as part of the therapeutic treatment has shown to improve or slow the worsening in the quality of life of patients with Alzheimer's disease and their caregivers. Future research focused on these patients should use a more exhaustive methodology and make a more detailed description of these kind of interventions.


Author(s):  
Jie Wang ◽  
Shan Mao ◽  
Jian Wang ◽  
Yuhuan Jiao ◽  
Xiangfeng Zhang ◽  
...  

This study aimed to investigate the effect of Ginkgo biloba extract on the cognitive function and neurotransmitter levels in rats with vascular dementia (VD) and its mechanism of action. 50 male Sprague Dawley rats were selected for this study, and the vascular dementia model was established by permanent occlusion of bilateral common carotid arteries of rats. Of which 40 rats were then divided into four groups (n=10):  vascular dementia group, low-dose, middle-dose and high-dose ginkgo biloba extract groups respectively; another 10 rats were allocated to sham operation group. Rats  in  low, middle and high dose groups were received 5, 10 and 20 mg/kg/d Ginkgo biloba extract via tail vein, respectively, while model group and sham group received an equal volume of normal saline. Morris water maze was used to evaluate the cognitive function of rats. After behavioral observation, these rats were sacrificed for detecting the level of acetylcholine (ACh), dopamine (DA) and 5-hydroxytryptamine (5-HT) in brain tissue. Ginkgo biloba extract can significantly improve the cognitive function of rats with vascular dementia, the mechanism may be correlated with the fact that the extract can obviously increase the levels of ACh, 5-HT and DA, as well as inhibit the activity of AChE.


2017 ◽  
Vol 8 (1) ◽  
Author(s):  
Joseph Mathew Antony ◽  
Ian Weaver ◽  
Matthew Rueffer ◽  
Najla Guthrie ◽  
Malkanthi Evans

AbstractCognition is comprised of the faculties: perception, creativity, intuition, and ratiocination. Optimal levels of cognition are needed for independent functioning and balanced living. With an aging population that continues to grow, dietary supplements that tilt the balance towards maintenance of cognition are being marketed for vulnerable populations facing these challenges. Randomized clinical trials provide the causal inference necessary to define the efficacy of emerging nutraceuticals. Cognition testing, in particular, requires a battery of tests that encompass all brain regions involved in cognition so as to provide endpoints necessary for product validation. The lack of well controlled studies for comparison analyses, limited sample sizes, ambiguous dosages, and poor cognitive measures result in data that cannot be compared across studies to determine the efficacy of supplements claiming to enhance cognition. Clinical trials for the nutraceutical industry should consider the multifaceted nature of supplements, where clinical endpoints must be comprehensive while remaining feasible. Combining endpoints of cognition with physiological biomarkers of immunity and metabolism to arrive at a global index for cognitive health may be necessary for claim substantiation in order to fully justify and scientifically validate improvements in cognitive health. The issues and needs of a global index will be discussed here.


1998 ◽  
Vol 59 (12) ◽  
pp. 881-888 ◽  
Author(s):  
Kaj Winther ◽  
Carsten Randløv ◽  
Eydbjørg Rein ◽  
Jesper Mehlsen

Sign in / Sign up

Export Citation Format

Share Document